Artículo de investigación publicado en Frontiers in veterinary science

19 de noviembre de 2025

Introduction: Development of vaccines to preserve and improve human and animal health requires effective protective antigens, delivery platforms, and adjuvants. The immunostimulant based on heat-inactivated Mycobacterium bovis (IV) was developed to boost protective immune response in different animal species against pathogen infection and tick infestations.
Methods: In this study, a serum proteomics approach was used with functional annotations and enrichment network analysis for the characterization of immune pathways and biomarkers associated with parenteral administration of one, two, or three IV doses in the wild boar (Sus scrofa) animal model. An independent False Discovery Rate (FDR) analysis with the target-decoy approach provided by ProteinPilot™ was used, and positive identifications were considered when identified proteins reached a 1% FDR. Furthermore, pathogen surveillance was also performed to evaluate the IV treatment effect.
Results: The proteomics analysis identified a total of 205 proteins, of which 97 displayed significant differential representation with 64 and 33 over (e.g., C4a, C5, C6, C7, and C9) and underrepresented (e.g., C3), respectively, in response to treatment. Results showed that IV administration activated both innate and adaptive immune responses through humoral immunity, regulation of the actin cytoskeleton pathway, coagulation cascade, and complement system. A single or two doses of IV significantly increased the activities of the classical, alternative, and lectin complement pathways. Moreover, a tendency was observed towards reducing seroprevalence in IV-treated wild boar over time for the causative agents of tuberculosis (Mycobacterium tuberculosis complex), pneumonia (Mycoplasma hyopneumoniae), and Aujeszky`s disease (porcine herpesvirus type 1).
Discussion: These results support a role for IV in stimulating immune and anti-inflammatory responses with possible application in different vaccine formulations for the control of infectious diseases

Villar M., Rodriguez O., Vaz-Rodrigues R., Pardo-Reyes AE., Rafael M., Artigas-Jerónimo S ., de la Fuente G., Fernandez de Mera IG., Juste RA., Sevilla IA., Dominguez L., Gortazar C. y de la Fuente J.

Complement system activation in wild boar (Sus scrofa) following parenteral administration of heat-inactivated Mycobacterium bovis

Complement system activation in wild boar (Sus scrofa) following parenteral administration of heat-inactivated Mycobacterium bovis

	Sanidad y Biotecnología (SaBio). Instituto de Investigación en Recursos Cinegéticos (IREC). Consejo Superior de Investigaciones Científicas (CSIC). Universidad de Castilla La Mancha (UCLM). Gobierno de Castilla-La Mancha (JCCM).
	Biochemistry Section. Faculty of Science and Chemical Technologies. Universidad de Castilla La Mancha (UCLM).
	BP 30. Sidi Allal el Bahraoui.
	Sabiotec.
	Instituto Vasco de Investigación y Desarrollo Agrario (NEIKER). Gobierno Vasco.
	Basque Research and Technology Alliance (BRTA).
	Servicio Regional de Investigación y Desarrollo Agroalimentario (SERIDA). Gobierno del Principado de Asturias.
	Servicio de Micobacterias (MYC). Centro de Vigilancia Sanitaria Veterinaria (VISAVET). Universidad Complutense (UCM).
	Departamento de Sanidad Animal. Facultad de Veterinaria. Universidad Complutense (UCM).
	Departament of Veterinary Pathobiology. Center for Veterinary Health Sciences (CVHS). Oklahoma State University (OSU).